ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

CKD in Primary Care Full Webinar

Springer Healthcare IME

S. Seidu, B. Itzhak, M. Ungan, L. Moist

New Research: Side Effect of GLP1

Susan Brian

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Choosing the Optimal Blood Pressure Medication for My Hypertensive P…

Rivka Ayalon

An Introduction to Tirzepatide for Weightloss

Susan Brian

The Role of Food Additives Based in Potassium, Phosphorus and Sodium…

Valeria Cecchini

Artificial Intelligence & CHAT GPT in Nephrology

University of Colorado Department of Medicine

S. Ambruso

Predictors of Poor Response to Semaglutide for Weight Management

Ploutarchos Tzoulis

Chapter 4 - How Can Primary Care Be Supported to Bridge the Chronic …

Springer Healthcare IME

S. Seidu, B. Itzhak, M. Ungan, L. Moist

Understanding the Phenomenon of 'Ozempic Face'

San Francisco Dermatological Society (SF Derm)

F. Kamangar

Long-term Complications of Transplants

PKD Foundation

N. Issa

AUA 2024 Insights: " GLP-1 Receptor Agonists and Men's Health"

Insights from AUA 2024 Annual Meeting

E. Pozzi

Etiology of Obesity

Beverly Tchang

Carbohydrate-Insulin Model: A Physiological Perspective on the Obesi…

The Texas Heart Institute

D. Ludwig

Transitioning to Adult Care in ADPKD / ARPKD

PKD Foundation

E. Hartung

Guideline Recommended Therapy in Patients With Diabetic Kidney Disea…

Heart in Diabetes (HiD)

M. R. Weir